Charnwood Molecular and Reach Separations

Over the last five years, Charnwood Molecular and Reach Separations have forged a highly effective working relationship, allowing for the efficient delivery of high purity achiral and chiral compounds to our Discovery clients through a seamless, collaborative working model.

To enable the rapid progress expected of collaborative medicinal chemistry programs, Charnwood Molecular has adopted a continuous improvement approach, resulting in considerable investment in state-of-the-art equipment to streamline our workflows and better facilitate the synthesis, purification and analysis of the compounds that we prepare on behalf of our growing international client base. For purification purposes, the company’s scientists have direct access to a suite of Biotage Isolera systems, as well as a Waters mass-directed preparatory HPLC system. Routine analyses are performed at Charnwood Molecular using a combination of Waters Acquity I-Class UPLC-MS and Agilent 1260 LCMS systems.

For purification and analysis of challenging chiral targets, Charnwood Molecular collaborates with the industry-leading purification experts at Reach Separations, who are co-located in the Stuart Adams building at BioCity, Nottingham, to develop robust methods for the effective separation of chiral compounds. Reach Separations also assist Charnwood Molecular with particularly challenging achiral separations when the need arises.

Dr James Hitchin, Head of Medicinal Chemistry at Charnwood Molecular, commented: ‘Charnwood Molecular is now working in collaboration with a number of strategic partners to expedite the progression of our clients’ pre-clinical drug assets through the discovery phase and into development. We have also made significant investments in our own infrastructure, as well as recruiting new staff at different levels of our organisation, to allow us to perform as efficiently as possible, to the highest possible standards. The combination of the synthetic and medicinal chemistry expertise of our own chemists with the extensive analytical and purification capabilities provided to us by our colleagues at Reach Separations, allows us to rapidly address our clients’ demands for the delivery of high quality products to support their programs’.

Peter Ridgway, Director of Business Development at Reach Separations added: ‘At Reach Separations we like the idea that our clients view us as the virtual laboratory at the end of their corridor where they can send samples to for purification and analysis. In the case of Charnwood Molecular we are actually the lab at the end of the corridor! The two companies have established an excellent working relationship over the last five years. In some small way we have supported Charnwood Molecular in becoming more competitive in the CRO market place with a rapid turnaround of purified material and a strong level of expertise in chromatography’.

About Charnwood Molecular
Charnwood Molecular is a leading CRO providing Drug Discovery and early, pre-clinical Development services. Founded in 1998, we support the Drug Discovery activities of organisations from virtual start-ups to large Pharmaceutical companies. We offer a flexible service from the synthesis of single compounds to the full management of Medicinal Chemistry projects. For further information about Charnwood Molecular please see: www.charnwood-molecular.com

About Reach Separations
Reach Separations is a highly specialised Chromatography Purification service based at BioCity in Nottingham, UK that was founded in 2012. With a vast level of expertise in the fields of chiral, reverse phase and normal phase chromatography, Reach Separations has rapidly established itself as a key provider of Outsource purification to the pharmaceutical, fine chemical, agrochemical and academic sectors across the UK and into Mainland Europe. Please see: www.reachseparations.com

Charnwood Molecular have recently taken delivery of a DrySyn MAXI heating system from Asynt Ltd, to successfully and reproducibly scale up syntheses at the company’s Loughborough research facility.

Chanrwood Molecular - DrySyn MAXI heating system

Dr Michael McKenzie, Head of Operations, said: “Here at Charnwood Molecular our experienced preclinical R&D team routinely investigate the development of small scale medicinal chemistry routes in order to facilitate the timely supply of up to 500g of a final compound to our clients for testing. Delivery of this initial key amount of compound for preclinical studies is accompanied by a new, robust and transferable scale-up route to go beyond that quantity in clinical phases. Investment in DrySyn technology has allowed us to reproducibly scale-up our customers’ synthetic reactions from the milligrams to hundreds of grams scale.”

Used with a conventional laboratory hotplate stirrer, DrySyn MAXI heating blocks provide rapid, safe and controllable heating up to 250ºC, with excellent reaction visibility and powerful stirring. The DrySyn MAXI block accommodates any standard 3000ml round-bottom flask, and using an insert the block is easily adapted for 2000ml flasks. Heat-resistant handles on the heating block make for greater safety and convenience when moving these large flasks around the laboratory. Provision is made for a temperature probe should temperature feedback control or monitoring be required.

Using standard round-bottomed reaction flasks, the DrySyn MAXI heating system provides safe and accurate temperature control for synthesis, distillation and reflux operations when larger volumes (up to 3 litres) are in use. For further scale-up, the DrySyn SuperMAXI heating block is available for both 4000ml and 5000ml sized flasks.

20 yrs logo and new strap - transparent
Research Group Leader (Medicinal Chemistry), Nottingham, UK

Operating from state-of-the-art research facilities in Loughborough and BioCity, Nottingham, UK, Charnwood Molecular is a leading Contract Research Organisation, providing medicinal chemistry, process research and other synthetic chemistry services to the global pharmaceutical, biotechnology and chemical industries.

As part of an ongoing expansion to meet the rising demand for our services, we are now looking to recruit an exceptional individual to contribute to the leadership and management of our project teams at BioCity.

Reporting directly to the Head of Medicinal Chemistry, you will be a key member of our leadership team; your role will involve the design and implementation of new synthetic routes, supporting the day-to-day activities of your team of research chemists, and liaising directly with our clients and collaborators.

Candidate specification:
A BSc, Masters or PhD degree in synthetic organic or medicinal chemistry along with at least 3 years of relevant experience within a biotech, pharmaceutical or contract chemical research organisation.

Previous experience of leading small teams to support drug discovery projects at the hit-to-lead and lead optimization stages would be an advantage, but is not essential.

At Charnwood Molecular we recognise that a company’s real strengths lie in the people that it employs. Our strategy is to recruit the most talented individuals to bring a wealth of creative talent to our team. This is a permanent role offering an competitive salary, benefits and training package, including company pension scheme and medical insurance.

If you have the drive and ambition to help shape the development of a dynamic research-led company located in the heart of the vibrant City of Nottingham, then we look forward to receiving your application.

Please note that all applicants should be eligible to work in the UK.

Call to action:
To be considered, or for further informal discussions, please submit a detailed CV and covering letter: recruitment@charnwood-molecular.com

Charnwood and Forendo

A two-year-long discovery chemistry collaboration between Charnwood Molecular and Forendo Pharma has seen compounds move from discovery to pre-clinical development.

Charnwood Molecular and Forendo Pharma have been collaborating since September 2015, with Charnwood Molecular synthesising challenging steroidal analogues of a hit compound initially identified at Forendo Pharma. Multi-centred lead optimisation efforts led to the identification of a development candidate, for which Charnwood Molecular’s pre-clinical Process Development group scouted various routes for larger-scale synthesis. Studied processes initially delivered multi-gram quantities within the collaboration, before being used by Forendo Pharma to access multi-kilogram quantities of the compound they are now progressing into development.

Dr Robin Wilkes, Director of Business Development at Charnwood Molecular commented: ‘Charnwood Molecular is being increasingly engaged by small companies looking to quickly progress pre-clinical assets into drug development. The infrastructure and partnerships we have developed over the past few years now allow us to do that. We have thoroughly enjoyed working alongside such an excellent collaborator as Forendo Pharma, who we wish every success in taking their development candidates forward’.

“Charnwood Molecular was consistently solving difficult synthetic routes and achieving good results, bringing new ideas and delivering all expectations” added T. Linnanen, Forendo Pharma, Head of Drug Discovery.

About Forendo Pharma

Forendo Pharma is a drug development company that specialises in diseases associated with tissue specific hormone mechanisms. The company is a world-leading innovator in the endometriosis field, with two active programs. Fispemifene, which was developed as part of the company’s men’s health program, is currently used in clinical practice for the treatment of male urological conditions. For further information about Forendo Pharma please see: www.forendo.com

About Charnwood Molecular

Charnwood Molecular is a leading CRO providing Drug Discovery and early, pre-clinical Development services. Founded in 1998, we support the Drug Discovery activities of organisations from virtual start-ups to large Pharmaceutical companies. We offer a flexible service from the synthesis of single compounds to the full management of Medicinal Chemistry projects. For further information about Charnwood Molecular please see: www.charnwood-molecular.com

conference1

We’ve now extended our event schedule into 2018 and we have the following representatives at these upcoming events:

Attending: Professor Steven Allin
Event: Heterocyclic and Synthesis Group January Meeting and AGM, London
Date: 12 January 2018
________________________________________________________________

Attending: Dr Robin Wilkes
Event: Organofluorine Chemistry: Synthetic Methods and Applications, London
Date: 9 February 2018
________________________________________________________________

Attending: Dr Robin Wilkes
Event: The BMCS Mastering MedChem IV. 4th RSC-BMCS Symposium on Mastering Medicinal Chemistry, Glasgow
Date: 14 March 2018
________________________________________________________________

Should you wish to meet us at any of these, please email us at:
info@charnwood-molecular.com

Charnwood Molecular has been a key sponsor of Keele University PhD student, Lucy Tunstall, during her trek across the Sahara Desert in aid of St Lukes Hospice in Winsford, Cheshire.

Charnwood Molecular - Lucy Returns

The trek covered a 50km stretch of difficult Saharan terrain, and the trip to and from the desert itself took nine hours, giving some indication of the remoteness of the trail!

Lucy’s group covered the 50 kilometres over a four day period, and in doing so raised over £25,000 for St Lukes Hospice. The group used social media to maintain a blog throughout the trek.

The expedition involved scaling endless sand dunes, battling scorching temperatures by day and sleeping out under the stars.

Lucy has now returned from the group’s base in Marrakesh and is back working and completing her PhD studies. Lucy’s work on the development of novel anti-malarials at Keele is co-funded by Charnwood Molecular.

Lucy is a keen fund raiser and this is just the latest of a series of challenges that she has undertaken to raise funds for St Lukes Hospice.

“I am most grateful to Charnwood Molecular for sponsoring me” said Lucy. “Without the company’s support, I would not have met my funding target to participate, and I am so pleased that I got to undertake this challenge”, she added.

conference1

We are attending the following events and conferences in the coming months.

Event: ELRIG Drug Discovery 2017
Date: 3-4 October 2017
Venue: Liverpool, UK
Charnwood Molecular Representative: Dr Robin Wilkes
________________________________________________________________

Event: Catalysis without Precious Metals
Date: 17 October 2017
Venue: SCI, London, UK
Charnwood Molecular Representative: Alexandre Jolibois
________________________________________________________________

Event: 2nd Fibrosis Meeting
Date: 10 November 2017
Venue:SCI, London
Charnwood Molecular Representative: Professor Steven Allin & Dr Robin Wilkes
________________________________________________________________

Event: WPC Europe
Date: 15-17 November 2017
Venue: Lisbon, Portugal
Charnwood Molecular Representative:Dr Robin Wilkes
________________________________________________________________

Event: Recent Trends and Technologies in Medicinal Chemistry towards Medicines of the Future
Date: 8 December 2017
Venue: NHLI, London
Charnwood Molecular Representative: Dr Robin Wilkes
________________________________________________________________

Event: High Potency ADCs – from discovery to the clinic
Date: 11 December 2017
Venue: Cambridge, UK
Charnwood Molecular Representative: Professor Steven Allin
________________________________________________________________

If you would like to meet any of our representatives at these events, please email:
info@charnwood-molecular.com

Charnwood Molecular received recognition as a finalist in this year’s East Midlands Chamber Business Awards in the “Small Business of the Year” category on Friday evening.

EMA awards line up altered

Photo Caption: from l to r - Dr Mike McKenzie, Paul Hughes, Dr Robin Wilkes, Professor Steven Allin, Dr David Lathbury & Dr James Hitchin.

Professor Steve Allin, Managing Director of Charnwood Molecular, was delighted with the news:
“As we approach our twentieth anniversary as a company, this nomination is testament to the hard work and commitment of the entire team, past and present, at Charnwood Molecular. In that time, and fuelled by significant expansion of our global client base, we have made significant investments into our infrastructure leading to an expansion in our provision in discovery chemistry and process research services, and this nomination recognises our collective efforts in our drive to achieving excellence in our services.”

The award – which was open to organisations employing up to 75 full-time members of staff – recognises companies that have achieved consistent growth backed by a strong financial performance.

We’re recruiting again for a variety of roles, including: Group Leaders, Medicinal and Synthetic Organic Chemists, and Process Research Chemists.

Operating from state-of-the-art research facilities in Loughborough and BioCity (Nottingham), UK, Charnwood Molecular is a leading Contract Research Organisation providing medicinal chemistry, process research and chemical development, and other synthetic chemistry services to the global pharmaceutical, biotechnology and chemical industries.

As part of an ongoing expansion to meet the rising demand for our services, we are looking to recruit a number of experienced individuals to join our project teams in a variety of roles, including: as Group Leaders, Medicinal and Synthetic Organic Chemists, and Process Research Chemists.

Candidate specification:

Ideally PhD qualified, with experience in the following areas:

• Synthetic Organic Chemistry
• Drug Discovery
• Lead Optimisation
• Process Research / Chemical Development

We would also like to hear from graduate level chemists who have several years experience in the industry.

We can offer a competitive salary and benefits, including a company pension scheme.

At Charnwood Molecular we recognise that a company’s real strengths lie in the people that it employs. Our strategy is therefore to employ the most talented chemists to bring a wealth of creative experience to our team. If you have the drive and ambition to help shape the development of a vibrant and dynamic research-led company, then we look forward to receiving your application.

To be considered for these positions please submit a detailed CV and covering letter to:

recruitment@charnwood-molecular.com

We are recruiting for a Business Development Executive to lead on our European operations.

This exciting BD Executive role requires a committed self-starter who is driven to respond proactively to business opportunities and creatively grow the CML business, specifically in Europe. The role requires excellent communication, problem-solving and influencing skills as well as the ability to work effectively as part of a small but growing team. The role may suit an individual with a technical background, with some customer-facing experience, who is now looking to develop their career with a commercial focus, at a particularly exciting stage of the company’s development.

Key Responsibilities
• Revenue generation for assigned territories (Europe) to agreed levels
• Account management of client accounts
• New business development, to grow and enhance the CML business in assigned territories (Europe)
• Arranging client meetings and attending business events
• Reporting progress through our business development infrastructure

Applicant Requirements
We envisage candidates for this exciting position will have some, if not all, of the following attributes:
• Scientific background, to BSc level or beyond
• Previous experience in a customer-facing/BD role within a chemical, pharmaceutical or life sciences environment, though candidates with a strong desire to now develop this area of your career after laboratory experience would also be considered
• Excellent communication skills
• Willingness to travel as required to develop business opportunities

Salary & Location
We offer a competitive salary and benefits, including a company pension scheme. Dependent on experience, this role may be company or home office based, though frequent attendance at the company’s sites would be expected.

Deadline for Applications: We request applications are submitted by 15th October 2017.

If you are interested in applyng for the role, please send your CV, with a covering letter to
recruitment@charnwood-molecular.com